Business Wire Industry News

Wednesday, October 5, 2022

Revitalist and Wake Network Joins Forces with Retired Delta Force, Command Sergeant Major Tom Satterly Addressing Veterans Access to Mental Health Resources

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #education--REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist'' or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), Revitalist and Wake Network join forces with Tom Satterly, one of the most highly regarded Special Operations operators in American military history to address Veteran mental health. Veterans in the United States are the highest risk population to lose their lives due to limited access, ineffective treatment options, and cost restraints. Ac

Wednesday, October 5, 2022

Valence Discovery Grows Leadership Team with Key Drug Discovery Hires

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Valence Discovery (“Valence”), a leader in AI-driven drug discovery harnessing the power of computation and fit-for-purpose data generation to design differentiated small molecules, announced today the expansion of its leadership team with the additions of Guillaume Barbe, Ph.D. as Vice President, Head of Drug Discovery, Mike Nolan, Ph.D. as Vice President, Head of Biology, and Brian DeChristopher, Ph.D. as Senior Director, Head of Chemical Sciences

Tuesday, October 4, 2022

BetterUp Appoints Psychologist Adam Grant as Chairman of Newly Launched Center for Purpose and Performance

SAN FRANCISCO--(BUSINESS WIRE)--Today BetterUp®, the human transformation company, announced that renowned psychologist Adam Grant, a bestselling author and current BetterUp Science Board member, is expanding his role with the company to serve as Chairman of BetterUp’s newly launched Center for Purpose and Performance. With an innovative research and convening agenda, Grant will drive the Center’s mission of partnering with industry leaders to deepen understanding of the intersections of well-b

Tuesday, October 4, 2022

Zymeworks Reminds Shareholders to Vote FOR its Redomicile

VANCOUVER, British Columbia & SEATTLE, Wash.--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reminds shareholders that the deadline for voting FOR the Company’s plan to become a Delaware corporation (the “Redomicile”) is 9:00 a.m., Pacific Time, on October 5, 2022. If you require assistance voting your proxy, please contact Kingsdale Advisors at 1-855-476-7981 (within North Ameri

Tuesday, October 4, 2022

BioTalent Canada calls for applications for New I.D.E.A.L. Bioscience Employer Recognition Program

OTTAWA, Ontario--(BUSINESS WIRE)-- #HR--BioTalent Canada today announced that its recently launched I.D.E.A.L. Bioscience Employer™ recognition program is now accepting applications. This new employer recognition program, which represents Inclusivity, Diversity, Equity, and Accessibility Leadership, will recognize organizations in Canada’s bio-economy embodying the diverse and inclusive corporate principles needed to promote growth and success in the sector. “The evidence proves diverse teams, led by

Monday, October 3, 2022

Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: Stifel 2022 Healthcare Conference. Zymeworks’ management will participate in one-on-one meetings and present on November 15th – 16th in New York, NY. Jefferies London Healthcare Conference. Zymeworks’ management will participate

Monday, October 3, 2022

BioTalent Canada Helps Employers Navigate Impending Talent Shortage Through National Occupational Standards

OTTAWA, Ontario--(BUSINESS WIRE)-- #HR--Today, BioTalent Canada launched new resources to help bio-economy employers adopt National Occupational Standards (NOS) into their recruitment and retention strategies. Included in the resources are seven additional NOS profiles, 23 executive summaries, and a “How-to” video for employers, job seekers and academia to integrate these valuable tools into their talent management and development plans. The standards, whose establishment was funded in part by the Go

Monday, October 3, 2022

ScaleReady Introduces the Cue® Cell Processing System From Fresenius Kabi

ST. PAUL, Minn.--(BUSINESS WIRE)--ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi and Wilson Wolf, announced today the market launch of the Cue Cell Processing System from Fresenius Kabi, available exclusively from ScaleReady. Cue, an automated small volume cell processing system, can precisely concentrate, wash, dilute, formulate and aliquot cell suspensions. Cue automates critical labor-intensive and highly variable tasks in the manufacturing workflow. This autom

Friday, September 30, 2022

NeuPath Provides Strategic Update, Announces Board and Executive Changes

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today provided an update on leadership changes, as well as its strategic growth plan to significantly accelerate the growth of its best-in-class and coordinated continuum of care for patients across Canada who suffer from pain and pain-related musculoskeletal conditions. Leadership changes Effective today, for hea

Friday, September 30, 2022

Oragenics Issues Letter to Shareholders

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy. To My Fellow Shareholders, As COVID-19 continues to impact the world’s population – albeit with far less dire consequences due to the availability of vaccines, therapeutics and better in-hospital care of

Friday, September 30, 2022

IMV Provides an Update on The VITALIZE Trial

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination with pembrolizumab and intermittent low-dose cyclophosphamide (CPA) in patients with relapses, refractory diff

Thursday, September 29, 2022

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that on September 27, 2022 it received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the minimum bid price requirement set

Thursday, September 29, 2022

Perimeter Medical Imaging AI Announces Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System

TORONTO & DALLAS--(BUSINESS WIRE)---- $PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) announced the commercial placement of its flagship Perimeter S-Series OCT system at a hospital that is part of a major national healthcare system and one of the largest healthcare networks in North Texas. Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs. Jeremy Sobott

Thursday, September 29, 2022

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the initiation of enrollment in the Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate expressing the full-length spike proteins from the SARS-CoV-1 (SARS), SARS-CoV-2 (COVID-19), and MERS-CoV (MERS) viruses. Jeff Baxter, VBI’s P

Thursday, September 29, 2022

Rapid Dose Therapeutics to Participate in the Venture Mentoring Services Program in Partnership with Maryland Tech Council and Canada’s Trade Commissioner Service

BURLINGTON, Ontario--(BUSINESS WIRE)--Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is one of five Canadian companies accepted into this year’s Venture Mentoring Services program offered by the Maryland Tech Council (MTC) in partnership with the Canadian Trade Commissioner Service in Washington, DC. The MTC’s Venture Mentoring Services program is a comprehensive, team mentor approach with an

Thursday, September 29, 2022

Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, October 27. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, a

Thursday, September 29, 2022

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors. “This is an i